Here is the design of a clinical trial:

Official Title: Safety of Surgical Treatment In Severe Primary Pontine Hemorrhage Evacuation (STIPE): a Multicentric, Randomized, Controlled, Open-label Trial

Included conditions:
- Cerebrovascular Disorders
- Pontine Hemorrhage
- Primary
- Surgery

Study Armgroups:
- {'label': 'medical group', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients receive only medical treatment including active life support, nutritional support, homeostasis maintenance of the internal environment, and other symptomatic treatment.', 'interventionNames': ['Other: life support']}
- {'label': 'surgical group', 'type': 'EXPERIMENTAL', 'description': 'Patients receive intervention such as the evacuation of hematoma under craniotomy or by stereotactic puncture or neuroendoscopy.', 'interventionNames': ['Procedure: hematoma evacuation by craniotomy', 'Procedure: hematoma evacuation by stereotactic puncture', 'Procedure: hematoma evacuation by neuroendoscopy']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'hematoma evacuation by craniotomy', 'description': 'The intervention method of hematoma evacuation is under craniotomy.', 'armGroupLabels': ['surgical group']}
- {'type': 'PROCEDURE', 'name': 'hematoma evacuation by stereotactic puncture', 'description': 'The intervention method of hematoma evacuation is under stereotactic puncture.', 'armGroupLabels': ['surgical group']}
- {'type': 'PROCEDURE', 'name': 'hematoma evacuation by neuroendoscopy', 'description': 'The intervention method of hematoma evacuation is under neuroendoscopy.', 'armGroupLabels': ['surgical group']}
- {'type': 'OTHER', 'name': 'life support', 'description': 'The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。', 'armGroupLabels': ['medical group']}

Primary Outcomes:
- {'measure': 'Safety Outcome Number 1: Rate of Mortality', 'description': 'Percentage of participants who died during the first 30 days after randomization.', 'timeFrame': '30 days from randomization'}
- {'measure': 'Safety Outcome Number 2: Rate of Cerebritis, Meningitis, Bacterial Ventriculitis', 'description': 'Percentage of participants who had a bacterial brain infection (cerebritis, meningitis, ventriculitis) within 30 days of randomization.', 'timeFrame': '30 days from randomization'}
- {'measure': 'Safety Outcome Number 3: Rate of Symptomatic Rebleeding', 'description': 'The difference in the rate of symptomatic rebleeding 72 hours post surgery.', 'timeFrame': '72 hours post surgery'}

Please estimate the sample size based on the assumption: 
5% significance level (two-sided), 80% power, 6% missing rate during follow-up
Sample size
        The calculation of sample size depends on the outcome distribution from our previous work.11 It was reported that 70.4% patients died with MT while only 30.4% died undergoing surgical HE after sPPH. A sample size of 60 would be required to demonstrate a significant level of 5% (two-sided) with 80% power. Considering the 6% missing rate during follow-up, the total sample size was 64 cases with 16 and 48 cases in MT and HE group, respectively.